DOUBLE EDGE EFFECT OF DPP4 INHIBITOR SITAGLIPTIN, A TYPE-2 ANTI-DIABETIC DRUG, ON INFLAMMATION, INJURY AND CANCER

This publication has 56 references indexed in Scilit:

• Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway
  Pharmacological Reports, 2016
• Type 2 diabetes and risk of cancer
  BMJ, 2014
• The Role of Adiponectin in Cancer: A Review of Current Evidence
  Endocrine Reviews, 2012
• Evaluating Treatment Algorithms for the Management of Patients With Type 2 Diabetes Mellitus: A Perspective on the Definition of Treatment Success
  Clinical Therapeutics, 2011
• Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
  Diabetes Care, 2011
• Diabetes and Cancer
  Diabetes Care, 2010
• Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
  Pharmacology & Therapeutics, 2009
• Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
  Journal of the American Pharmacists Association, 2009
• Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
  Diabetes, Metabolic Syndrome and Obesity, 2009
• The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
  New England Journal of Medicine, 1993